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The Model T and a Peek Behind the Curtain?
“Change is the law of life. And those who look only to the past or present are certain to miss the future.” 
– U.S. President John F. Kennedy
Change. The Future. Two similar, but complicated, concepts that many of us either fear due to uncertainty, or aggressively seek out due to the thrill of being on the cutting edge. If we’re paralyzed by uncertainty, it’s easy to get left behind as new and better opportunities emerge. On the flip side, it’s easy to get burned by constantly 
chasing “the next great thing.” Perhaps the most prudent course is to be constantly aware of what may lie on the hori-
zon, while maintaining a grounded realization of potential implications for the present and future. If only things were 
so simple! Further complicating matters, our openness to the change the future potentially holds is affected by many 
variables, including our current position in life when things are going well and seemingly “on autopilot,” we’re often 
more resistant to change; but if we’re down on our luck with “nothing to lose,” change can be much easier to embrace. 
Take, for instance, the automobile entrepreneur, Henry Ford, who revolutionized transportation around the 
world by innovating and “thinking outside the box.” He brought the moving assembly line to the automotive indus-
try, as well as around-the-clock factory shifts and local franchise dealerships, all while making the automobile af-
fordable for the masses. Ford was handsomely rewarded for his innovations. At its peak, Ford Motor Company held 
a 50% market share, and Henry Ford’s personal net worth in today’s dollars is estimated to have been $188 Billion 
(for perspective, that’s still $50B more than Bill Gates and Warren Buffett today...combined!) 
Yet even Ford had problems embracing change later in his career. At one point, his engineers saw the public’s 
desire for changes to the Model T that had brought Ford Motor Company to the pinnacle of the automobile industry 
(changes that their competitors began adopting), but Henry Ford refused to modify his design because “it wasn’t the 
Ford way” and because the intoxication of success had bred a false sense of security and an accompanying resistance 
to change. This myopic insistence on maintaining the status quo drove Ford Motor Company from 50% market 
share to the brink of closure under the same leader, within just a few years. In fact, if Henry Ford’s son hadn’t taken 
over the company and made the necessary changes, Ford Motor Company would not exist today. As the old mantra 
goes, “To stay still, is to fall behind.”
Similarly, a myriad of innovations and technologies are poised to potentially transform the practice of eye care in 
the coming decades. Let’s take a brief peek behind the curtain at some of these, and consider what impact they may 
have on the quality of care we provide our patients and how we provide it.
PHARMACEUTICALS
It’s nearly impossible to track even a fraction of all the compounds that are currently in various stages of research 
and development in the pharmaceutical industry: from medications such as a topical broad-spectrum antiseptic 
(yes, an antiseptic, not an antibiotic) paired with a corticosteroid for treatment of both adenoviral and bacterial 
conjunctivitis in children and adults,1 to a topical, selective vascular endothelial growth factor (VEGF) inhibitor 
for wet age-related macular degeneration, diabetic retinopathy, and other forms of macular edema, whose efficacy 
rivals the currently available intravitreal anti-VEGFs.2 In addition, how about an oral compound that’s a synthetic 
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derivative of testosterone and which enhances endothelial cell barrier function to treat diabetic macular edema?3
In the field of glaucoma, it’s been over two decades since the introduction of a truly novel class of medication, but 
that may soon change. Latanoprostene bunod is close to coming to market as a topical medication that breaks down 
into latanoprost acid, the well-established prostaglandin analog, and nitric oxide, which further enhances aqueous 
outflow by acting directly on trabecular meshwork.4 Further, an entirely novel class of glaucoma medications called 
Rho-kinase (ROCK) inhibitors is being developed by several pharmaceutical companies. ROCK inhibitors relax 
smooth muscle in trabecular meshwork to increase aqueous outflow, while also lowering episcleral venous pres-
sure and further facilitating outflow, both of which are unique mechanisms of action that are not shared with any 
currently available glaucoma medications. Several ROCK inhibitors have also been paired with Nor-epinephrine 
Transport (NET) inhibitors, which suppress aqueous production, to give a triple mechanism of action.5 Combina-
tions of ROCK and NET inhibitors paired with a prostaglandin analog to enhance uveoscleral outflow are also being 
developed, which could offer a quadruple mechanism of action. Compounds such as these are just a small sampling 
of what’s in the pipeline from various ophthalmic pharmaceutical companies.
DRUG DELIVERY
Not only are new compounds being created, but drug-delivery methods are also poised to potentially undergo 
radical changes. Sustained-release medications in the form of next-generation fornix-based inserts, punctal plug 
devices, intracanalicular inserts, and medicated contact lenses are in various stages of development by multiple 
manufacturers.6,7,8 An ocular iontophoresis unit with a Prager shell-like device that uses a small electric current to 
drive medication into the eye is also being developed.8 3-D printing and nanotechnology are on the verge of drasti-
cally improving the efficacy of current and future pharmaceutical agents. What if we could prescribe medications 
at lower concentrations and dose them much less frequently than ever before, while at the same time drastically 
increasing their efficacy and reducing or possibly even eliminating unwanted side effects?
ASSISTIVE DEVICES
For our patients who have lost visual acuity, contrast sensitivity, and/or visual field, multiple companies are devel-
oping next-generation wearable devices that attach to a patient’s spectacle frame, or come with a standalone frame, 
and audibly guide patients through the environment, and can even read labels and printed materials on command.
GENE THERAPY
No area of medicine holds more promise than gene therapy. In the U.S., the first gene therapy for inherited diseases, 
in this case for inherited retinal diseases, was recently approved.9 Meanwhile, a husband and wife team at the Uni-
versity of Washington are investigating a cure for color vision defects in primates,10 and are now moving into human 
trials using human recombinant DNA and a benign adenoviral vector to deliver a gene patch. While gene therapy is 
still a subject of debate, research is progressing rapidly in many other areas of eye care, including repairing and replac-
ing damaged retinal pigment epithelial (RPE) cells and corneal epithelial cells. In both cases, pluripotent stem cells 
are harvested from a patient’s own skin, then differentiated into the appropriate cell type. Imagine the possibility of 
curing, rather than just treating, the chronic and debilitating ocular diseases we encounter so often with our patients! 
OCUL AR SURGERY
Cataract surgery is also poised to have increasingly more procedures performed without general anesthesia, without 
the need for patients to use post-operative medications, and with multifocal intraocular lenses offering better vision 
(and less loss of contrast sensitivity). Numerous innovations in IOL design are being tested, including an auto-focusing 
IOL that uses an embedded computer chip and a self-contained battery. Glaucoma surgeries continue to become less 
invasive, including an ultrasound-based therapy that works much like selective laser trabeculoplasty (SLT) and newer 
aqueous shunt designs. The next generation of refractive surgery procedures is also emerging, such as small incision 
lenticule extraction (SMILE) and various corneal inlay procedures like KAMRA and Raindrop to treat presbyopia.
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PHOROPTERS
Closer to home, how about a potential seismic shift in the way we refract patients? The developers of a “vir-
tual phoropter” claim that it uses wavefront technology and computer-controlled, variable-power “virtual lenses” 
to drastically increase refractive accuracy versus traditional phoropters.11 In combination with newly developed 
manufacturing technologies, this “virtual refracting platform” would allow spectacle lenses to be precisely manu-
factured to levels of refractive correction previously unseen. This platform also does away with the Snellen visual 
acuity chart by having the patient view a high-definition photo of a real-world situation during refraction. Could we 
even imagine refracting without a phoropter or without a Snellen chart?
We’ve only scratched the surface, as the list of new and emerging eye-care technologies goes on and on. Who 
could predict which, if any, of these might actually be “the next great thing”? What we do know is that just a fraction 
of new innovations are ever able to overcome the hurdles of disappointing real-world results, potentially exorbitant 
cost, lackluster adoption rates, poor design, and/or inadequate marketing to attain success, and only a microscopic 
portion of those will truly become game-changers. However, the sheer volume of innovations in the eye-care pipe-
line assures that there will be some game changers, so we would do well to remember the young Henry Ford, who 
embraced change, who innovated, and who adopted technology to improve the quality of life for those around him, 
and not follow the lead of the old Henry Ford, who fell behind and nearly ruined his company with a futile and myo-
pic stubbornness to maintain the status quo in the face of progress. 
Let’s not fear what’s behind the curtain, but rather honestly vet each innovation and advocate to protect patients 
from those that don’t meet standards of care, while finding ways to embrace and appropriately implement new tech-
nologies and treatments that enhance our patients’ quality of life and expand the scope of care we provide. If we do, 
the future of eye care is bright indeed! l
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